CLAIMS

1. Combination product comprising:

(i) at least one substance capable of inhibiting CSF-1 activity and/or at least one nucleic acid, comprising at least one sequence coding for a substance capable of inhibiting CSF-1 activity, and,

(ii) at least one substance having at least a cytotoxic activity and/or at least one nucleic acid, comprising at least one sequence coding for a substance having at least a cytotoxic activity.

2. Combination product according to claim 1, characterised in that the substance capable of inhibiting CSF-1 activity is an oligonucelotide.

3. Combination product according to claim 2, characterised in that said oligonucleotide is capable of hybridising at the region between the nucleotide in position 97 and the nucleotide in position 99 inclusive of SEQ ID No. 1.

4. Combination product according to claim 2, characterised in that said oligonucleotide is capable of hybridising at the region between the nucleotide in position 121 and the nucleotide in position 450 inclusive of SEQ ID No. 1.

5. Combination product according to claim 4, characterised in that said oligonucleotide is capable of hybridising at the region between the nucleotide in position 131 and the nucleotide in position 391 inclusive of SEQ ID No. 1.

6. Combination product according to claim 5, characterised in that said oligonucleotide is capable of hybridising at the region between the nucleotide in

position 135 and the nucleotide in position 152 inclusive of SEQ ID No. 1.

7. Combination product according to claim 5, characterised in that said oligonucleotide is capable of hybridising at the region between the nucleotide in position 284 and the nucleotide in position 301 inclusive of SEQ ID No. 1.

8. Combination product according to claim 5, characterised in that said oligonucleotide is capable of hybridising at the region between the nucleotide in position 341 and the nucleotide in position 358 inclusive of SEQ ID No. 1.

9. Combination product according to any of claims 2 to 8, characterised in that said oligonucleotide comprises 8 to 30 nucleotides.

10. Combination product according to claim 9, characterised in that said oligonucleotide comprises 12 to 25 nucleotides.

11. Combination product according to claim 1, characterised in that the substance capable of inhibiting CSF-1 activity is an antibody.

12. Combination product according to any of claims 1 to 11, characterised in that the substance having at least a cytotoxic activity is selected from the substances interacting with DNA, antimetabolites, topoisomerase inhibitors, spindle agents and cytostatic agents.

13. Combination product according to any of claims 1 to 11, characterised in that the substance having at least a cytotoxic activity is a tumour-related antigen.

14. Combination product according to any of claims 1 to 11, characterised in that the substance having at

least a cytotoxic activity is selected from cytokines, polypeptides showing a chemo-attraction activity, proteins coded by a suicide gene, anti-angiogenic protein factors and polypeptides showing a cellular apoptosis activation activity.

15. Oligonucleotide, capable of inhibiting CSF-1 expression, 8 to 100 nucleotides in length, characterised in that it is capable of hybridising at the region between the nucleotide in position 121 and the nucleotide in position 450 inclusive of SEQ ID No. 1.

16. Oligonucleotide according to claim 15, characterised in that it is capable of hybridising at the region between the nucleotide in position 131 and the nucleotide in position 391 inclusive of SEQ ID No. 1.

17. Oligonucleotide according to claim 16, characterised in that it is capable of hybridising at the region between the nucleotide in position 135 and the nucleotide in position 152 inclusive of SEQ ID No. 1.

18. Oligonucleotide according to claim 16, characterised in that it is capable of hybridising at the region between the nucleotide in position 284 and the nucleotide in position 301 inclusive of SEQ ID No. 1.

19. Oligonucleotide according to claim 16, characterised in that it is capable of hybridising at the region between the nucleotide in position 341 and the nucleotide in position 358 inclusive of SEQ ID No. 1.

20. Oligonucleotide according to any of claims 15 to 19, characterised in that it comprises 8 to 30 nucleotides.

21. Oligonucleotide according to claim 20, characterised in that it comprises 12 to 25 nucleotides.

22. Oligonucleotide according to any of claims 15 to 21, characterised in that it is combined with a substance which combines with nucleic acids.

23. Oligonucleotide according to claim 22, characterised in that said substance which combines with nucleic acids is selected from cationic lipids, polypeptides and cationic polymers.

24. Nucleic acid characterised in that it comprises a sequence coding for an oligonucleotide according to any of claims 15 to 22.

25. Nucleic acid according to claim 24, characterised in that it is a plasmid vector.

26. Nucleic acid according to claim 24, characterised in that it is a viral vector.

27. Nucleic acid according to any of claims 24 to 26, characterised in that it is combined with a substance which combines with nucleic acids.

28. Nucleic acid according to claim 27, characterised in that said substance which combines with nucleic acids is selected from cationic lipids, polypeptides and cationic polymers.

29. Formulation comprising at least one oligonucleotide according to any of claims 15 to 23 and a pharmaceutically acceptable vehicle.

30. Formulation comprising at least one combination product according to any of claims 1 to 14 and a pharmaceutically acceptable vehicle.

31. Use of a combination product according to claims 1 to 14, for the preparation of a medicinal product for the treatment of cancer.

32. Use of a substance capable of inhibiting CSF-1 activity for the preparation of a medicinal product to improve the efficacy of an antitumoral treatment.

33. Use of an oligonucleotide according to claims 15 to 23 for the preparation of a medicinal product intended for the treatment of cancer.